Table 3.
Micro Computed Tomography (µCT) of the femoral mid-diaphysis.
| Ct.Ar (mm2) | Tt.Ar (mm2) | Ct.Ar/Tt.Ar (%) | Ct.Th (µm) | Ma.Ar (mm2) | J (mm4) | TMD (mg/cm3 of HA) | |
|---|---|---|---|---|---|---|---|
| Base | 0.73 ± 0.03 | 1.71 ± 0.08 | 43.0 ± 2.0 | 160 ± 6 | 0.97 ± 0.07 | 0.33 ± 0.03 | 1145 ± 10 |
| Ctrl | 0.77 ± 0.04 | 1.72 ± 0.07 | 44.6 ± 1.8 | 171 ± 8 a | 0.95 ± 0.05 | 0.35 ± 0.03 | 1163 ± 11 a |
| BTX | 0.65 ± 0.03 a,b | 1.68 ± 0.07 | 38.9 ± 1.3 a.b | 146 ± 5 a,b | 1.03 ± 0.05 a,b | 0.30 ± 0.03 a,b | 1156 ± 7 a |
| BTX+Zol | 0.75 ± 0.03 c | 1.69 ± 0.06 | 44.5 ± 1.3 c | 169 ± 5 a,c | 0.94 ± 0.04 c | 0.33 ± 0.03c | 1165 ± 11 a |
16-week-old C57BL/6J female mice immobilized with botulinum toxin (BTX) and treated with zoledronic acid (Zol) compared with baseline (Base) and control (Ctrl) mice. Cortical area (Ct.Ar), tissue area (Tt.At), cortical area fraction (Ct.Ar/Tt.Ar), cortical thickness (Ct.Th), marrow area (Ma.Ar), polar moment of inertia (J), tissue mineral density (TMD), and hydroxyapatite (HA).
a
denotes a significant difference (p<0.05) from Base,
b
denotes a significant difference (p<0.05) from Ctrl, and
c
denotes a significant difference (p<0.05) from BTX. Mean ± SD.